<DOC>
	<DOCNO>NCT00049764</DOCNO>
	<brief_summary>The purpose study determine : 1 . Whether drotrecogin alfa ( activate ) help child severe sepsis survive condition often recover fast child receive drotrecogin alfa ( activate ) . 2 . Whether drotrecogin alfa ( activate ) minimize long term disability associate severe sepsis . 3 . The side effect might associate drotrecogin alfa ( activate ) administration child severe sepsis .</brief_summary>
	<brief_title>Investigation Efficacy Safety Drotrecogin Alfa ( Activated ) Pediatric Severe Sepsis</brief_title>
	<detailed_description>The primary objective demonstrate drotrecogin alfa ( activate ) compare placebo reduce severe-sepsis-induced organ dysfunction assess time complete resolution composite cardiovascular , respiratory , renal organ failure pediatric patient severe sepsis . Secondary objective include : ( 1 ) ass whether treatment drotrecogin alfa ( activate ) reduce 28-day all-cause mortality pediatric patient severe sepsis compare placebo patient , ( 2 ) evaluate effect drotrecogin alfa ( activate ) individual organ dysfunction ( cardiovascular , respiratory , renal , hepatic , hematologic , neurologic , cutaneous ) , ( 3 ) demonstrate drotrecogin alfa ( activate ) improve patient outcome assess Pediatric Overall Performance Category ( POPC ) scale , ( 4 ) demonstrate drotrecogin alfa ( activate ) reduce major amputation ( wrist , ankle , face , genitals ) pediatric patient Neisseria meningitidis ( proven suspect ) and/or purpura fulminans , ( 5 ) demonstrate drotrecogin alfa ( activate ) antithrombotic anti-inflammatory property . The safety objective evaluate whether drotrecogin alfa ( activate ) acceptable safety profile administer pediatric patient severe sepsis .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Suspected proven acute infection . Abnormally high low core body temperature Cardiovascular dysfunction require use vasoactive drug ( , dopamine , dobutamine , epinephrine ) result severe sepsis . Respiratory dysfunction require use mechanical ventilation result severe sepsis . Patients increase risk bleeding . Patients high risk intracranial bleed . Patients undergone bone marrow transplant . Patients endstage renal disease . Patients whose family primary care physician unwilling allow transfusion blood product .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>